Weak Agonistic LPS Restores Intestinal Immune Homeostasis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Generated by gram-negative bacteria, lipopolysaccharides (LPSs) are one of the most abundant and potent immunomodulatory substances present in the intestinal lumen. Interaction of agonistic LPS with the host myeloid-differentiation-2/Toll-like receptor 4 (MD-2/TLR4) receptor complex results in nuclear factor κB (NF-κB) activation, followed by the robust induction of pro-inflammatory immune responses. Here we have isolated LPS from a common gut commensal, Bacteroides vulgatus mpk (BVMPK), which provides only weak agonistic activity. This weak agonistic activity leads to the amelioration of inflammatory immune responses in a mouse model for experimental colitis, and it was in sharp contrast to strong agonists and antagonists. In this context, the administration of BVMPK LPS into mice with severe intestinal inflammation re-established intestinal immune homeostasis within only 2 weeks, resulting in the clearance of all symptoms of inflammation. These inflammation-reducing properties of weak agonistic LPS are grounded in the induction of a special type of endotoxin tolerance via the MD-2/TLR4 receptor complex axis in intestinal lamina propria CD11c + cells. Thus, weak agonistic LPS represents a promising agent to treat diseases involving pathological overactivation of the intestinal immune system, e.g., in inflammatory bowel diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Endotoxin tolerance: new mechanisms, molecules and clinical significance
Biswas, S. K., & Lopez-Collazo, E. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.07.009 · Cited by 1,318
Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans
Vatanen, T., Kostic, A. D., d’Hennezel, E., Siljander, H., Franzosa, E. A., Yassour, M., Kolde, R., Vlamakis, H., Arthur, T. D., Hämäläinen, A.-M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.007 · Cited by 1,289
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.-A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302578 · Cited by 930
Matsunaga, N., Tsuchimori, N., Matsumoto, T., & Ii, M. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068064 · Cited by 597
Ochoa-Repáraz, J., Mielcarz, D. W., Wang, Y., Begum-Haque, S., Dasgupta, S., Kasper, D. L., & Kasper, L. H. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.29 · Cited by 507
The Commensal Microbiota and Enteropathogens in the Pathogenesis of Inflammatory Bowel Diseases
Chassaing, B., & Darfeuille–Michaud, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.054 · Cited by 443 · cited 1×
“DISCUSSION BVMPK belongs to the gram-negative bacterial phylum Bacteroidetes, representing one of the two most prominent phyla in the mammalian gut.(29,30) However, the proportion of Bacteroidetes in the intestinal microbiota is dependent on the inflammatory status of the gut.”
Background
Cited by
The impact of the gut microbiome on extra-intestinal autoimmune diseases
Miyauchi, E., Shimokawa, C., Steimle, A., Desai, M. S., & Ohno, H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00727-y · Cited by 367
Self-citationLai, H.-C., Lin, T.-L., Chen, T.-W., Kuo, Y.-L., Chang, C.-J., Wu, T.-R., Shu, C.-C., Tsai, Y.-H., Swift, S., & Lu, C.-C. (2022) · Gut · doi:10.1136/gutjnl-2020-322599 · Cited by 331
A Journey from Structure to Function of Bacterial Lipopolysaccharides
Di Lorenzo, F., Duda, K. A., Lanzetta, R., Silipo, A., De Castro, C., & Molinaro, A. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01321 · Cited by 322
Self-citationLeveraging diet to engineer the gut microbiome
Wolter, M., Grant, E. T., Boudaud, M., Steimle, A., Pereira, G. V., Martens, E. C., & Desai, M. S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00512-7 · Cited by 211
Self-citationLin, T.-L., Shu, C.-C., Chen, Y.-M., Lu, J.-J., Wu, T.-S., Lai, W.-F., Tzeng, C.-M., Lai, H.-C., & Lu, C.-C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00554 · Cited by 143
The Gut Microbiome as a Regulator of the Neuroimmune Landscape
Yu, L. W., Agirman, G., & Hsiao, E. Y. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-014237 · Cited by 75
Sun, L., Zhang, Y., Dong, W., Sun, J., Wang, T., Shao, F., Dai, H., Han, J., Wang, W., Wang, S., et al. (2025) · iMeta · doi:10.1002/imt2.70066 · Cited by 15
“Hypo ‐ acylated gut bacterial LPS have been shown to induce beneficial immunomodulatory responses in inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), and obesity [21 – 24].”
Metadata
- Authors
- Steimle, A., Michaelis, L., Di Lorenzo, F., Kliem, T., Münzner, T., Maerz, J. K., Schäfer, A., Lange, A., Parusel, R., Gronbach, K., Fuchs, K., Silipo, A., Öz, H. H., Pichler, B. J., Autenrieth, I. B., Molinaro, A., & Frick, J.-S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 27
- Issue
- 11
- Pages
- 1974-1991
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2962804268
- Cited by
- 96
- References
- 15
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.